Form 4: Integra Lifesciences Director Receives RSU Grant

Christian S. Schade, a Director at Integra Lifesciences Holdings Corp., was granted 17,700 Restricted Stock Units (RSUs) on May 7, 2026, vesting one year later.

Summary

• Christian S. Schade, a Director of Integra Lifesciences Holdings Corp. (IART), received a grant of 17,700 Restricted Stock Units (RSUs) on May 7, 2026.
• These RSUs are part of the company's Fifth Amended and Restated 2003 Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of IART common stock.
• The RSUs will vest in full on the one-year anniversary of the grant date, May 7, 2027.
• Mr. Schade has elected to defer the receipt of the vested shares, with delivery scheduled for the calendar year following his termination of service on the Board of Directors, unless a later year is elected.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard equity grant to a director rather than significant financial results or strategic shifts.

Positives

• Director receives equity award, indicating continued commitment and alignment with company performance.
• Grant of 17,700 RSUs valued at the common stock price on the grant date.

Risks

• The value of the RSUs is subject to the future performance of Integra Lifesciences Holdings Corp. stock.
• Potential for forfeiture of RSUs if vesting conditions are not met (though not explicitly stated as a risk in this filing, it's inherent to RSUs).

Future Outlook

The future outlook for the value of the RSUs depends on the company's stock performance and the timing of Mr. Schade's departure from the Board.

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice in the life sciences industry to incentivize long-term performance and align executive interests with shareholders. The structure of this RSU grant, including the deferral election, is typical for senior leadership.

Stakeholder Impact

• Shareholders: The grant of RSUs represents potential future dilution, but also signals director commitment.
• Employees: The equity incentive plan framework is a standard component of compensation for key personnel.
• Management: The grant aligns director incentives with the company's stock performance.

Next Steps

• Vesting of RSUs on May 7, 2027.
• Delivery of vested shares in the calendar year following Mr. Schade's termination of service on the Board of Directors.

Key Dates

Keywords

Integra Lifesciences, IART, Form 4, Restricted Stock Units, RSU Grant, Director Compensation, Equity Incentive Plan, Christian S. Schade, Beneficial Ownership